cohort and later analyzed using paired and unpaired t-tests and linear regressions to determine significant correlations.
PURPOSE:
Contralateral prophylactic mastectomy at the time of therapeutic mastectomy for unilateral breast cancer rates have more than tripled in the past decade despite the lack of evidence for survival benefit. We investigated morbidity and patient-reported quality of life (QoL) outcomes of performing a contralateral prophylactic mastectomy followed by bilateral breast reconstruction (CBR) compared to unilateral mastectomy and breast reconstruction (UR).
METHODS:
Using IRB-approved, prospectively collected breast reconstruction registry, we queried pre-and postoperative data from patients who underwent CBR or UR at our institution. We used simple and multiple linear regression to compare morbidity and QoL changes between study groups (CBR vs. UR).
RESULTS:
Between 2010 and 2015, 211 patients underwent CBR (n=86, 40.8%) or UR (n=125, 59.2%). While the unadjusted surgical morbidity was significantly higher for the BR group at 60 days post-tissue expander placement (p<0.001), it was not significantly different between groups immediately before final reconstruction, at 60 days post-final reconstruction, orat 1 year post-final reconstruction. After adjusting for possible cofounders, CBR patients did not have a statistically significant difference in pre-to post-reconstruction changes of QoL when compared to UR in the domains of Satisfaction with Breast (p=0.62), Psychosocial Well-being (p=0.71), Sexual Well-being (p=0.85), and Chest Physical Well Being (p=0.09).
CONCLUSIONS:
Our findings suggest that performing a CBR for unilateral breast cancer is not associated with higher QoL compared to UR. There was a higher rate of shortterm complications for staged breast reconstruction following tissue expander placement for the CBR group but not at long-term. PURPOSE: The popularity of abdominally based free flap breast reconstruction has grown tremendously over the past decade. However, controversy persists regarding the safety of performing these operations in individuals with a prior history of abdominal surgery.
EVALUATING THE SAFETY OF

METHODS:
We performed a retrospective review of all patients who underwent abdominally based free flap breast reconstruction between 2008 and 2016. Patient demographics, operative details, and postoperative outcomes were assessed. All patients had at least 3 months of follow up for study inclusion.
RESULTS:
We identified 132 patients who underwent 186 abdominally based free flaps. 70 patients (104 breast reconstructions) had a prior history of abdominal surgery. 57 patients (73 breast reconstructions) had no prior abdominal surgeries. Five patients underwent simultaneous gynecologic surgery at the time of their free flap harvest; these patients were excluded from analysis. The groups were appropriately matched with respect to BMI, race/ethnicity, smoking status, and comorbidities. We found no difference in overall abdominal complications requiring surgical intervention (14.5% vs 15.8%, p= 0.84). Incidence of abdominal bulge was greater in the study group (11.4% vs 3.5%, p = 0.099), however this was not statistically significant. Breast related complications were also similar between the two groups. There were no total flap losses in either group. Rates of fat necrosis requiring excision were 15.4% vs 15.1%, p = 0.954.
CONCLUSION:
Prior history of abdominal surgery does not significantly increase complications in abdominally based free flap breast reconstruction, and should not preclude patients from undergoing these reconstructions. NSMs with neoadjuvant chemotherapy were significantly more likely to have implant explantation (p=0.0015) and complete nipple necrosis (p=0.0004) compared to those with no chemotherapy. Compared to NSMs with no chemotherapy, those with adjuvant chemotherapy were significantly more likely to have hematoma formation (p=0.0021). Those with neoadjuvant chemotherapy were significantly more likely to have explantation (p=0.0239) and complete nipple necrosis (p=0.0021) compared to those with adjuvant chemotherapy.
THE EFFECT OF NEOADJUVANT
NSMs with both neoadjuvant and adjuvant chemotherapy were significantly more likely to have complete nipple necrosis compared to those with neoadjuvant chemotherapy only and adjuvant chemotherapy only (p<0.0001). No differences were observed in NSMs with neoadjuvant chemotherapy and adjuvant radiation compared to NSMs with neoadjuvant chemotherapy alone.
CONCLUSIONS:
NSM is safe to perform in the setting of neoadjuvant and adjuvant chemotherapy. However, neoadjuvant chemotherapy appears to increase complications; a synergistic effect between neoadjuvant and adjuvant chemotherapy likely yields overall greatest risk.
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